Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study

Inflammatory Bowel Disease

Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study

J Crohns Colitis.

Parragi L, Fournier N, Zeitz J, Scharl M, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group

doi: 10.1093/ecco-jcc/jjy040.

Inflammatory Bowel Disease

Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study

J Crohns Colitis.

Burisch J, Katsanos KH, Christodoulou DK, Barros L, Magro F, Pedersen N, Kjeldsen J, Vegh Z, Lakatos PL, Eriksson C, Halfvarson J, Fumery M, Gower-Rousseau C, Brinar M, Cukovic-Cavka S, Nikulina I, Belousova E, Myers S, Sebastian S, Kiudelis G, Kupcinskas L, Schwartz D, Odes S, Kaimakliotis IP, Valpiani D, D'Incà R, Salupere R, Zammit SC, Ellul P, Duricova D, Bortlik M, Goldis A, Kievit HAL, Toca A, Turcan S, Midjord J, Nielsen KR, Andersen KW, Andersen V, Misra R, Arebi N, Oksanen P, Collin P, de Castro L, Hernandez V, Langholz E, Munkholm P1, Epi-IBD Group

doi: 10.1093/ecco-jcc/jjy154.

Inflammatory Bowel Disease

Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis

Eur J Gastroenterol Hepatol.

O'Connell J, Rowan C, Stack R, Harkin G, Parihar V, Chan G, Breslin N, Cullen G, Dunne C, Egan L, Harewood G, Leyden J, MacCarthy F, MacMathuna P, Mahmud N, McKiernan S, McNamara D, Mulcahy H, Murray F, O'Connor A, O'Toole A, Patchett S, Ryan B, Sheridan J, Slattery E, Doherty G, Kevans D

doi: 10.1097/MEG.

Inflammatory Bowel Disease

Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy

J Crohns Colitis.

Panés J, Lindsay JO, Teich N, Lindgren S, Colombel JF, Cornillie F, Flynn HA, Huyck S, Stryszak P, Yao R, Philip G, Reinisch W

doi: 10.1093/ecco-jcc/jjz048.

Inflammatory Bowel Disease

Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study

Aliment Pharmacol Ther.

Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN

doi: 10.1111/apt.15177.

RECOMMENDED

Inflammatory Bowel Disease

Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study

Inflamm Bowel Dis.

Biancone L, Armuzzi A, Scribano ML, Castiglione F, D'incà R, Orlando A, Papi C, Daperno M, Vecchi M, Riegler G, Fries W, Alvisi P, Meucci G, Mocciaro F, Rogai F, Festa S, Guidi L, Testa A, Spina L, Renna S, Viola A, Patturelli M, Di Mitri R, Frankovic I, Calabrese E, Petruzziello C, De Cristofaro E, Sena G, Ruffa A, Neri B, Rossi A, Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).

doi: 10.1093/ibd/izz155.

Inflammatory Bowel Disease

Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis

Inflamm Bowel Dis.

Adedokun OJ, Gunn GR 3rd, Leu JH, Gargano C, Xu Z, Sandborn WJ, Rutgeerts P5, Shankar G

doi: 10.1093/ibd/izz003.

Inflammatory Bowel Disease

JAK inhibitors safety in ulcerative colitis: practical implications

J Crohns Colitis.

Agrawal M, Kim ES, Colombel JF

doi: 10.1093/ecco-jcc/jjaa017.

Inflammatory Bowel Disease

A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment^®^MMX® for active, mild-to-moderate ulcerative colitis

United European Gastroenterol J.

Danese S, Hart A, Dignass A, Fiorino G, Louis E, Bonovas S, D'Haens G, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L

doi: 10.1177/2050640619864848.

Related content

Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study

Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study

Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis

Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy

Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study

Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study

Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis

JAK inhibitors safety in ulcerative colitis: practical implications

A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX® for active, mild-to-moderate ulcerative colitis

A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment^®^MMX® for active, mild-to-moderate ulcerative colitis